What is the ROCE (Return on Capital Employed) of Haemonetics this year?
The ROCE of Haemonetics is 0.22 undefined this year.
Haemonetics ROCE 2024
Haemonetics ROCE
0.22
Ticker
HAE
ISIN
US4050241003
WKN
881782
In 2024, Haemonetics's return on capital employed (ROCE) was 0.22, a 65.47% increase from the 0.13 ROCE in the previous year.
Haemonetics Aktienanalyse
What does Haemonetics do?
Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Haemonetics's Return on Capital Employed (ROCE)
Haemonetics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Haemonetics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Haemonetics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Haemonetics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Haemonetics stock
How has the ROCE (Return on Capital Employed) of Haemonetics developed compared to the previous year?
The ROCE of Haemonetics has increased by 65.47% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Haemonetics?
A high Return on Capital Employed (ROCE) indicates that Haemonetics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Haemonetics?
A low ROCE (Return on Capital Employed) can indicate that Haemonetics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Haemonetics impact the company?
An increase in the ROCE of Haemonetics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Haemonetics affect the company?
A decrease in ROCE of Haemonetics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Haemonetics?
Some factors that can affect Haemonetics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Haemonetics so important for investors?
The ROCE of Haemonetics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Haemonetics take to improve the ROCE?
To improve the ROCE, Haemonetics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Haemonetics pay?
Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Haemonetics?
The current dividend yield of Haemonetics is .
When does Haemonetics pay dividends?
Haemonetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Haemonetics?
Haemonetics paid dividends every year for the past 0 years.
What is the dividend of Haemonetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Haemonetics located?
Haemonetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemonetics from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did Haemonetics pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of Haemonetics in the year 2023?
In the year 2023, Haemonetics distributed 0 USD as dividends.
In which currency does Haemonetics pay out the dividend?
The dividends of Haemonetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemonetics
Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
